Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Orchestra BioMed Holdings, Inc. - Ordinary Shares
(NQ:
OBIO
)
6.300
+0.240 (+3.96%)
Streaming Delayed Price
Updated: 12:40 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Orchestra BioMed Holdings, Inc. - Ordinary Shares
Orchestra BioMed Reports Second Quarter 2024 Financial Results and Provides a Business Update
August 12, 2024
From
Orchestra BioMed Holdings, Inc.
Via
GlobeNewswire
Orchestra BioMed Announces Appointment of Cardiovascular Device Industry Expert John Mack to Board of Directors
July 30, 2024
From
Orchestra BioMed Holdings, Inc.
Via
GlobeNewswire
Precision Neuroscience Expands Executive Team as Brain–Computer Interface Industry Rapidly Advances
July 23, 2024
Jayme Strauss and Mike Kaswan join as Chief Clinical and Commercial Officer and Chief Financial Officer, respectively, as the company progresses toward FDA clearance
From
Precision Neuroscience
Via
GlobeNewswire
Orchestra BioMed Announces Further Details on In-Person R&D Day in New York Featuring Key Opinion Leaders to Discuss AVIM Therapy Program in Hypertensive Pacemaker Patients on June 11, 2024
June 04, 2024
From
Orchestra BioMed Holdings, Inc.
Via
GlobeNewswire
Orchestra BioMed to Participate in Jefferies Global Healthcare Conference
May 22, 2024
From
Orchestra BioMed Holdings, Inc.
Via
GlobeNewswire
Orchestra BioMed Reports First Quarter 2024 Financial Results and Provides a Business Update
May 13, 2024
From
Orchestra BioMed Holdings, Inc.
Via
GlobeNewswire
Orchestra BioMed Announces AVIM Therapy Global Intellectual Property Estate Reaches 110 Issued Patents
April 30, 2024
From
Orchestra BioMed Holdings, Inc.
Via
GlobeNewswire
Orchestra BioMed to Host In-Person R&D Day in New York on AVIM Therapy Program in Hypertensive Pacemaker Patients on June 11, 2024
April 30, 2024
From
Orchestra BioMed Holdings, Inc.
Via
GlobeNewswire
Orchestra BioMed Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update
March 27, 2024
From
Orchestra BioMed Holdings, Inc.
Via
GlobeNewswire
Orchestra BioMed Announces Appointment of Medical Device Industry Expert David Pacitti to Board of Directors
March 26, 2024
From
Orchestra BioMed Holdings, Inc.
Via
GlobeNewswire
Orchestra BioMed Demonstrates Strength of Cardiovascular Pipeline with Virtue® SAB and AVIM Therapy Presentations at CRT 2024 Annual Meeting
March 13, 2024
From
Orchestra BioMed Holdings, Inc.
Via
GlobeNewswire
Orchestra BioMed to Participate in Upcoming Investor Conferences
March 07, 2024
From
Orchestra BioMed Holdings, Inc.
Via
GlobeNewswire
Orchestra BioMed Announces Presentation of Results from Clinical Study Demonstrating Favorable Hemodynamic Effects of AVIM Therapy In Hypertensive Pacemaker Patients
March 06, 2024
From
Orchestra BioMed Holdings, Inc.
Via
GlobeNewswire
Orchestra BioMed Presents New Data Showing Sustained Clinically Meaningful Reduction in 24-Hour Ambulatory Systolic Blood Pressure in Hypertensive Pacemaker Patients Treated with AVIM Therapy for Over 3 Years
February 26, 2024
From
Orchestra BioMed Holdings, Inc.
Via
GlobeNewswire
Orchestra BioMed Reports Third Quarter 2023 Financial Results and Provides Business Update
November 13, 2023
From
Orchestra BioMed Holdings, Inc.
Via
GlobeNewswire
Orchestra BioMed Granted FDA Approval of IDE to Initiate BACKBEAT Pivotal Study of BackBeat CNT™ for the Treatment of Hypertension in Pacemaker Patients
September 19, 2023
From
Orchestra BioMed Holdings, Inc.
Via
GlobeNewswire
Orchestra BioMed Reports Second Quarter 2023 Financial Results and Provides Business Update
August 10, 2023
From
Orchestra BioMed Holdings, Inc.
Via
GlobeNewswire
Orchestra BioMed™ Granted FDA Approval of IDE for U.S. Pivotal Study of Virtue® Sirolimus AngioInfusion Balloon™ in Patients with Coronary In-Stent Restenosis
August 08, 2023
From
Orchestra BioMed Holdings, Inc.
Via
GlobeNewswire
Orchestra BioMed Set to Join Russell 3000® and other FTSE Russell Indexes
June 26, 2023
From
Orchestra BioMed Holdings, Inc.
Via
GlobeNewswire
Orchestra BioMed Appoints Bill Little as Executive Vice President of Corporate Development and Strategy and Andrew Taylor as Chief Financial Officer
June 07, 2023
From
Orchestra BioMed Holdings, Inc.
Via
GlobeNewswire
Orchestra BioMed to Present at the Jefferies Global Healthcare Conference
June 01, 2023
From
Orchestra BioMed Holdings, Inc.
Via
GlobeNewswire
Orchestra BioMed Reports First Quarter 2023 Financial Results and Provides Business Update
May 12, 2023
From
Orchestra BioMed Holdings, Inc.
Via
GlobeNewswire
Orchestra BioMed to Present at Upcoming Investor Conferences
March 07, 2023
From
Orchestra BioMed Holdings, Inc.
Via
GlobeNewswire
Orchestra BioMed Strengthens Senior Leadership Team
February 07, 2023
From
Orchestra BioMed Holdings, Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.